MedPath

Tianjin Medical University Cancer Institute & Hospital

πŸ‡¨πŸ‡³China
Ownership
-
Employees
-
Market Cap
-
Website

Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy

Phase 2
Conditions
Esophageal Cancer
Interventions
Procedure: side-to-side stapled esophagogastric anastomosis
Procedure: circular-stapled esophagogastric anastomosis
First Posted Date
2010-11-16
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
40
Registration Number
NCT01242124
Locations
πŸ‡¨πŸ‡³

Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China

Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)

Not Applicable
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2010-04-06
Last Posted Date
2013-01-29
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
25
Registration Number
NCT01099124
Locations
πŸ‡¨πŸ‡³

Tianjin Medical University Cancer Institude and Hospital, Tianjin, China

Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction

Conditions
Malignant Biliary Obstruction
First Posted Date
2010-02-23
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
300
Registration Number
NCT01073514
Locations
πŸ‡¨πŸ‡³

Tianjin Medical University Cancer Institude and Hospital, Tianjin, Tianjin, China

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Phase 2
Suspended
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2009-09-29
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
102
Registration Number
NCT00986284
Locations
πŸ‡¨πŸ‡³

Tianjin Cancer Institute & Hospital, Tianjin, Tianjin, China

Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer

Phase 2
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Other: Radiation Therapy and EGFR-TKI target therapy
First Posted Date
2009-09-09
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
50
Registration Number
NCT00973310
Locations
πŸ‡¨πŸ‡³

Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China

Β© Copyright 2025. All Rights Reserved by MedPath